IFNA1 and neoplasm: Accordingly, a rational treatment approach may be combination therapy with ruxolitinib and IFN [274,275] enabling ruxolitinib to normalize a high-level of JAK-mediated pro-inflammatory cytokines [276], likely enhancing the capability of IFN to exert its effects by inhibiting clonal expansion and improving tumor immune surveillance [7,19,277].